OverviewSuggest Edit
Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.
| Type | Public | |
| Founded | 1997 | |
| HQ | Salt Lake City, UT, US | Map |
| Website | lipocine.com |
Recent NewsAll News
Key People/Management at Lipocine
Mahesh V. Patel
Chairman, President and Chief Executive Officer
Morgan Brown
Executive Vice President and Chief Financial Officer
Greg Bass
Executive Vice President and Chief Commercial Officer
Jyrki Mattila
Executive Vice President and Chief Business Officer
Anthony DelConte
Chief Medical Director
Lipocine Office Locations
Lipocine has offices in Salt Lake City and Trenton
Salt Lake City, UT, US (HQ)
675 Arapeen Dr #202
Trenton, NJ, US
3150 Brunswick Pike #130
Lipocine Financials and Metrics
Lipocine Revenue
Lipocine's revenue was reported to be $164.99 k in FY, 2019
| USD | |
|---|---|
Net income (Q2, 2020) | (6.4m) |
EBIT (Q2, 2020) | (4.2m) |
Market capitalization (19-Jan-2021) | 115.6m |
Closing stock price (19-Jan-2021) | 1.8 |
Cash (30-Jun-2020) | 13.8m |
EV | 108.1m |
Lipocine's current market capitalization is $115.6 m.
Annual
Quarterly
| USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 428.0k | 165.0k | ||||||||||||||||||||||||
General and administrative expense | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 1.2m | 1.9m | 1.0m | 871.8k | 1.1m | 1.1m | 1.7m | 4.4m | 3.2m | 1.4m | 1.8m | 2.0m | 2.7m | 1.7m | 1.7m | 930.1k | 1.2m | 1.4m | 1.4m | 2.1m | 2.0m |
R&D expense | 1.6m | 3.4m | 6.0m | 3.2m | 1.9m | 3.2m | 4.7m | 2.7m | 2.6m | 1.5m | 3.1m | 4.1m | 2.0m | 1.4m | 1.5m | 1.4m | 1.9m | 2.0m | 1.7m | 2.5m | 2.3m | |||||
Operating expense total | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 2.8m | 5.3m | 7.0m | 4.1m | 3.0m | 4.3m | 6.5m | 7.1m | 5.9m | 3.3m | 5.0m | 6.2m | 4.8m | 3.1m | 3.2m | 2.4m | 3.1m | 3.4m | 3.1m | 4.6m | 4.2m |
Annual
Quarterly
| USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 17.9k | 3.4k | 622.0 | 458.0 | 10.0 | 36.8m | 41.8m | 34.2m | 31.7m | 24.8m | 38.3m | 23.9m | 14.1m | 12.4m | 4.7m | 6.9m | 16.6m | 9.3m | 8.6m | 1.6m | 4.8m | 8.2m | 3.7m | 6.7m | 15.1m | 13.8m |
Prepaid Expenses | 251.7k | 256.4k | 1.3m | 285.9k | 186.5k | 181.3k | 347.8k | 268.9k | 154.0k | 457.4k | 262.0k | 88.6k | 453.4k | 248.0k | 113.3k | 728.5k | 411.4k | 148.9k | 754.5k | 373.4k | 147.3k | |||||
Current Assets | 622.0 | 458.0 | 10.0 | 37.1m | 42.0m | 35.4m | 32.0m | 25.0m | 44.1m | 42.3m | 38.6m | 33.2m | 29.4m | 27.1m | 27.9m | 26.1m | 31.6m | 25.3m | 22.6m | 23.0m | 19.6m | 17.3m | 21.0m | 23.5m | ||
PP&E | 34.8k | 27.6k | 24.6k | 40.7k | 82.7k | 79.9k | 82.9k | 108.3k | 119.9k | 111.7k | 96.3k | 89.3k | 82.2k | 32.3k | 27.9k | 23.4k | 15.1k | 11.3k | 7.4k | 2.8k | 2.0k |
Annual
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|
Net Income | (76.7k) | (10.6m) | (20.4m) | (18.2m) | (19.0m) | (21.0m) | (11.7m) | (13.0m) |
Depreciation and Amortization | 21.8k | 14.6k | 26.7k | 32.0k | 28.4k | 18.6k | 15.4k | |
Accounts Payable | 4.3k | 668.8k | (449.6k) | 200.8k | (261.2k) | 352.2k | 73.2k | 511.0k |
Cash From Operating Activities | (62.9k) | (8.6m) | (17.3m) | (15.4m) | (18.3m) | (16.7m) | (12.1m) | (11.7m) |
Quarterly
| USD | Q1, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.8k) | (71.7k) | (3.2k) | (6.3k) | (6.2m) | (5.3m) | (12.2m) | (16.3m) | (3.0m) | (7.2m) | (13.6m) | (7.0m) | (12.8m) | (16.0m) | (4.9m) | (11.0m) | (15.7m) | (2.7m) | (6.0m) | (8.4m) | (3.2m) | (6.7m) | (9.7m) | (5.8m) | (12.1m) |
Depreciation and Amortization | 15.7k | 3.0k | 6.1k | 9.4k | 4.3k | 8.7k | 19.6k | 6.7k | 15.5k | 23.7k | 7.1k | 14.2k | 21.3k | 5.3k | 9.7k | 14.2k | 3.9k | 7.7k | 11.6k | 799.0 | 1.6k | ||||
Accounts Payable | (612.0) | 3.1k | 5.7k | 1.1m | (254.0k) | (385.2k) | (627.9k) | 73.3k | 30.1k | 150.6k | 570.1k | 482.0k | 357.9k | 607.6k | 867.9k | 557.9k | (209.7k) | (191.5k) | (358.1k) | (153.6k) | (555.2k) | 689.2k | 472.7k | (275.4k) | |
Cash From Operating Activities | (5.1k) | (62.8k) | (119.0) | (567.0) | (4.5m) | (3.5m) | (11.1m) | (13.6m) | (3.0m) | (6.9m) | (12.4m) | (6.5m) | (11.7m) | (15.7m) | (3.1m) | (7.8m) | (12.4m) | (3.7m) | (6.5m) | (9.8m) | (3.0m) | (5.6m) | (8.4m) | (3.4m) | (7.5m) |
Lipocine Cybersecurity Score
Lipocine Online and Social Media Presence
Lipocine's Trends
Lipocine News and Updates
December 09, 2020
Lipocine Announces Tentative Approval of TLANDO™
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its oral...
December 09, 2020
Lipocine Announces Deletion of Unauthorized Changes to Company's Website
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine's website (www.lipocine.com), without authorization from...
December 04, 2020
Lipocine Provides New Regulatory Update on TLANDO™
SALT LAKE CITY, Dec. 4, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has informed the Company that it is continuing to work...
September 21, 2020
Thinking about buying stock in Wave Life Sciences, Axovant Gene Therapies, Lipocine Inc, Workhorse Group, or Cassava Sciences?
NEW YORK, Sept. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WVE, AXGT, LPCN, WKHS, and SAVA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 28, 2020
Thinking about buying stock in UnitedHealth, VBI Vaccines Inc, ADMA Biologics, Qutoutiao, or Lipocine Inc?
NEW YORK, Aug. 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UNH, VBIV, ADMA, QTT, and LPCN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
August 27, 2020
Thinking about buying stock in Northern Dynasty Minerals, Fluent Inc, Lipocine Inc, NetApp Inc., or HP?
NEW YORK, Aug. 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAK, FLNT, LPCN, NTAP, and HPQ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Lipocine Blogs
January 12, 2021
Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Conference Call Scheduled for 8:30 a.m. ET today
Lipocine Frequently Asked Questions
When was Lipocine founded?
Lipocine was founded in 1997.
Who are Lipocine key executives?
Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Greg Bass.
How many employees does Lipocine have?
Lipocine has 12 employees.
What is Lipocine revenue?
Latest Lipocine annual revenue is $165 k.
What is Lipocine revenue per employee?
Latest Lipocine revenue per employee is $13.7 k.
Who are Lipocine competitors?
Competitors of Lipocine include Rapafusyn Pharmaceuticals, Evrys Bio and Pherecydes Pharma.
Where is Lipocine headquarters?
Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.
Where are Lipocine offices?
Lipocine has offices in Salt Lake City and Trenton.
How many offices does Lipocine have?
Lipocine has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies